MB
MPM BioImpact Portfolio holdings
AUM
$577M
This Quarter Return
+8.2%
1 Year Return
+8.33%
3 Year Return
+241.63%
5 Year Return
+127.38%
10 Year Return
–
AUM
$667M
AUM Growth
+$667M
(+3.6%)
Cap. Flow
+$8.21M
Cap. Flow
% of AUM
1.23%
Top 10 Holdings %
Top 10 Hldgs %
55.8%
Holding
54
New
10
Increased
20
Reduced
7
Closed
11
Top Buys
| 1 |
Avidity Biosciences
RNA
|
$25.9M |
| 2 |
Rocket Pharmaceuticals
RCKT
|
$19.7M |
| 3 |
Twist Bioscience
TWST
|
$13.3M |
| 4 |
Aquestive Therapeutics
AQST
|
$8.95M |
| 5 |
Janux Therapeutics
JANX
|
$7.77M |
Top Sells
| 1 |
Alkermes
ALKS
|
$13.4M |
| 2 |
MORF
Morphic Holding, Inc. Common Stock
MORF
|
$12.6M |
| 3 |
AVDL
Avadel Pharmaceuticals
AVDL
|
$11M |
| 4 |
Xeris Biopharma Holdings
XERS
|
$10.9M |
| 5 |
Axsome Therapeutics
AXSM
|
$10.7M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
Aquestive Therapeutics
AQST
$478M
| $8.95M | 1.34% |
+1,796,750
| New | +$8.95M |
|
|
27
Janux Therapeutics
JANX
$1.38B
| $7.77M | 1.17% |
+171,105
| New | +$7.77M |
|
28
Viking Therapeutics
VKTX
$3.02B
| $7.66M | 1.15% |
120,982
+2,022
| +2% | +$128K |
|
29
Xenon Pharmaceuticals
XENE
$2.99B
| $6.53M | 0.98% |
+165,800
| New | +$6.53M |
|
30
Stoke Therapeutics
STOK
$1.08B
| $5.89M | 0.88% |
+479,452
| New | +$5.89M |
|
31
Repare Therapeutics
RPTX
$73.9M
| $5.64M | 0.85% |
1,639,849
| – | – |
|
32
Intellia Therapeutics
NTLA
$1.26B
| $5.5M | 0.82% |
267,557
-175,946
| -40% | -$3.62M |
|
33
Zentalis Pharmaceuticals
ZNTL
$123M
| $5.39M | 0.81% |
1,465,801
+15,801
| +1% | +$58.1K |
|
34
Trevi Therapeutics
TRVI
$871M
| $5.14M | 0.77% |
1,538,517
+28,343
| +2% | +$94.7K |
|
35
Wave Life Sciences
WVE
$1.27B
| $5.12M | 0.77% |
+624,471
| New | +$5.12M |
|
36
Arcturus Therapeutics
ARCT
$467M
| $5.09M | 0.76% |
+219,508
| New | +$5.09M |
|
37
Werewolf Therapeutics
HOWL
$62.6M
| $5.06M | 0.76% |
2,388,011
| – | – |
|
|
ADAP
38
Adaptimmune Therapeutics
ADAP
$13.9M
| $4.84M | 0.73% |
5,095,912
| – | – |
|
39
ALX Oncology
ALXO
$54.6M
| $4.39M | 0.66% |
2,409,862
+228,998
| +11% | +$417K |
|
40
PTC Therapeutics
PTCT
$4.41B
| $3.33M | 0.5% |
+89,715
| New | +$3.33M |
|
41
89bio
ETNB
$1.37B
| $2.44M | 0.37% |
330,000
-791,736
| -71% | -$5.86M |
|
42
Regenxbio
RGNX
$498M
| $525K | 0.08% |
50,000
-507,076
| -91% | -$5.32M |
|
43
Solid Biosciences
SLDB
$448M
| $80.3K | 0.01% |
+11,518
| New | +$80.3K |
|
|
44
Alkermes
ALKS
$4.95B
| – | – |
-557,556
| Closed | -$13.4M |
|
|
ALLK
45
DELISTED
Allakos
ALLK
| – | – |
-344,900
| Closed | -$345K |
|
|
AVDL
46
Avadel Pharmaceuticals
AVDL
$1.42B
| – | – |
-783,242
| Closed | -$11M |
|
|
47
Axsome Therapeutics
AXSM
$6.09B
| – | – |
-132,312
| Closed | -$10.7M |
|
48
Fulcrum Therapeutics
FULC
$353M
| – | – |
-1,444,851
| Closed | -$8.96M |
|
49
HilleVax
HLVX
$105M
| – | – |
-645,085
| Closed | -$9.33M |
|
50
Immatics
IMTX
$662M
| – | – |
-417,810
| Closed | -$4.85M |
|